Helse Bergen HF

26 trials 12 recruiting Academic / non-commercial

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

12 Recruiting

10 Completed trials

4 Countries active

49 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 8 Phase II/III: 1 Phase II: 12 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I (FiH): 1

Oversight events:

2 serious breaches 1 urgent safety measure across 3 trials

View oversight register →

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 1 Relapsing-remitting multiple sclerosis 1 Multiple sclerosis 1 Malignant glioma 1

Top IMPs

CYCLOPHOSPHAMIDE 2 DARATUMUMAB 2 DIAZEPAM 2 OCRELIZUMAB 2 PERFLUBUTANE 2 TENOFOVIR ALAFENAMIDE 2 ALEMTUZUMAB 1 ANTITHYMOCYTE IMMUNOGLOBULIN 1 BORTEZOMIB 1 BUSPIRONE HYDROCHLORIDE 1 CLADRIBINE 1 CORTISONE 1

All trials — page 2

26 total

The TAF-MS study Ended

2023-503814-62-00 Phase II 1 country NATALIZUMAB; TENOFOVIR ALAFENAMIDE
Experimental hypothermia using cold ambient temperature and drug-induced inhibition of shivering in awake, healthy volunteers: a crossover, … Ended

2023-506020-81-00 Phase II 1 country BUSPIRONE HYDROCHLORIDE; DIAZEPAM; EPINEPHRINE BITARTRATE; NALOXONE HYDROCHLORID…

Showing 25–26 of 26 trials

← All sponsors A–Z